e-learning
resources
Glasgow 2004
Monday 06.09.2004
Immunology in pulmonary diseases
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
OSA patients sera are characterized by the decreased angiogenic activity
J. Chorostowska-Wynimko, D. Radomska, D. Gorecka, E. Skopinska-Rozewska (Warsaw, Poland)
Source:
Annual Congress 2004 - Immunology in pulmonary diseases
Session:
Immunology in pulmonary diseases
Session type:
Thematic Poster Session
Number:
2231
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. Chorostowska-Wynimko, D. Radomska, D. Gorecka, E. Skopinska-Rozewska (Warsaw, Poland). OSA patients sera are characterized by the decreased angiogenic activity. Eur Respir J 2004; 24: Suppl. 48, 2231
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Definition and history of sarcoidosis
Adherence predictors to positive airway pressure (PAP) treatment in patients with obstructive sleep apnea (OSA)
The search for realistic evidence on the outcomes of obstructive sleep apnoea
Related content which might interest you:
TNFα and INFγ inducing capacity of sera from interstitial lung diseases (ILD) patients in relation to its angiogenic activity
Source: Eur Respir J 2001; 18: Suppl. 33, 410s
Year: 2001
The interaction between leptin and inflammatory markers in induced sputum in patients with moderate COPD
Source: Eur Respir J 2002; 20: Suppl. 38, 404s
Year: 2002
Carbocisteine in vivo reduces circulating miR-21 and IL-8 in exacerbated COPD patients
Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies
Year: 2019
COPD patients exhibit abnormally increased peripheral neutrophil stiffening not different from smokers with normal lung function
Source: Annual Congress 2009 - Functional insights into COPD
Year: 2009
Circulating inflammatory proteins and red blood cells antioxidant activity in patients with COPD
Source: Eur Respir J 2003; 22: Suppl. 45, 537s
Year: 2003
Serum levels of vascular endothelial growth factor (VEGF) are elevated in patients with acute exacerbated COPD
Source: Eur Respir J 2005; 26: Suppl. 49, 350s
Year: 2005
Hypercoagulability in patients with stable COPD assessed by coagulation factor levels
Source: Virtual Congress 2020 – Epidemiology, diagnosis and management of pulmonary embolism
Year: 2020
PP220 – Hypercoagulability in patients with stable COPD assessed by coagulation factor levels
Source: ERS Lung Science Conference 2021
Year: 2021
Destructive-cytolytic and peroxidase activity of bronchial granulocytes in asthma patients with different levels of disease control
Source: Virtual Congress 2021 – New insights into the airway immunology of lung disease
Year: 2021
MMP-9 expression and activity is incresed in the BAL of patients with acute exacerbation of COPD
Source: Annual Congress 2012 - Inflammatory mechanisms in COPD
Year: 2012
Increased levels of vascular endothelial growth factor in induced sputum in asthmatic patients
Source: Eur Respir J 2002; 20: Suppl. 38, 1s
Year: 2002
VEGF serum levels in COPD patients without pulmonary hypertension – a case control study
Source: International Congress 2018 – Biomarkers of COPD
Year: 2018
Increased CTGF expression of circulating fibrocytes in asthmatic patients with severe OSA - the role of HIF-1a and HDAC7
Source: International Congress 2018 – New kids on the block: novel molecular pathways and therapeutic targets in chronic lung diseases
Year: 2018
Factors influencing induced sputum cytokines and VEGF in a population of stable COPD patients
Source: Eur Respir J 2006; 28: Suppl. 50, 550s
Year: 2006
Angio-inhibitory activity and decreased leptin level in sera from obstructive sleep apnea syndrome (OSAS) patients
Source: Eur Respir J 2001; 18: Suppl. 33, 334s
Year: 2001
Elevated serum inflammatory markers in patients with stable COPD
Source: Annual Congress 2009 - Respiratory mechanics, tissue and cell dysfunction in pulmonary disease
Year: 2009
Is OSA an important risk factor for metabolic dysregulation in obese COPD patients
Source: International Congress 2018 – From continuous positive airway pressure (CPAP) and adherence to CPAP to asthma-COPD overlap syndrome (ACOS)
Year: 2018
Neutrophil activity assessed using a novel serological marker of human neutrophil elastase degraded calprotectin is elevated in patients with COPD or IPF
Source: Virtual Congress 2021 – Advanced in vitro models for drug discovery
Year: 2021
The markers of inflammatory process activity and fybrogenesis activity in patients with idiopathic pulmonary fibrosis
Source: Annual Congress 2012 - Diffuse parenchymal lung disease I
Year: 2012
CPAP decreases elevated plasma levels of soluble tumor necrosis factor-α receptor 1 in OSAS patients
Source: Annual Congress 2008 - Metabolic and sex-related aspects of obstructive sleep apnoea
Year: 2008
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept